Quality of Life, Efficacy, and Safety of Sequential Intravesical Gemcitabine + Docetaxel versus BCG for Non-Muscle Invasive Urinary Bladder Cancer: A Pilot Study
Conclusion: Gem/Doce combination intravesical therapy is a promising alternative to BCG for treatment of NMIBC, showing better QOL measures and lesser side effects.Urol Int
Source: Urologia Internationalis - Category: Urology & Nephrology Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Cystoscopy | Cytology | Docetaxel | Statistics | Study | Taxotere | Toxicology | Urology & Nephrology